Maintenance Therapy With Interleukin-2 for Childhood AML

Maintenance Therapy With Interleukin-2 for Childhood AML

Abstract. Despite significant progress in the treatment of pediatric acute myeloblastic leukemia (AML), relapse remains the commonest cause of death. Randomized ELAM02 trial questioned if maintenance therapy with interleukin-2 (IL2), for 1 year, improves disease-free survival (DFS). Patients aged 0...

Full description

Bibliographic Details
Main Authors: Arnaud Petit, Stéphane Ducassou, Thierry Leblanc, Marlène Pasquet, Alexandra Rousseau, Christine Ragu, Marine Cachanado, Brigitte Nelken, Yves Bertrand, Gérard Michel, Virginie Gandemer, Wendy Cuccuini, Odile Fenneteau, Hélène Lapillonne, Anne Auvrignon, André Baruchel, Guy Leverger, on behalf of SFCE
Format: Article
Language:English
Published: Wolters Kluwer 2018-12-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000159

Internet

http://journals.lww.com/10.1097/HS9.0000000000000159

Similar Items